# Index

# The prefix N refers to an entry in Appendix A on mathematical notation

Abnormal pathology 409- 13, 417 Absolute value 187, N509 Absorptiometry 279 Acoustic neuroma 275 Actuarial method 371 Adaptive designs 449 Adjusted  $R^{2}$  345- 6, 351 Adrenocorticotrophic hormone 442 Adverse reactions 45 Age 21, 390, 392, 461 and blood pressure 318 and body fat  $\%$  278, 282, 283, 286, 294, 298 gestational 42, 266, 310, 326, 425 of menarche 287, 298 and reference interval 423- 6 and road accidents 24- 6 - sex register 7 at tooth eruption 31 Agreement between categorical assessments 405- 8 between methods of measurement 277, 284, 396- 403, 484, 486 between observers 397, 403- 9 inter- rater 397, 403- 9 proportional 404, 407, 409 AIDS 413 Albumin 52, 54, 56, 57- 8, 136, 139, 148, 155, 160, 163- 4, 166- 7, 288, 390 Alcohol consumption 91, 103, 275, 297, 469 Aldosterone 503 Algorithm 111- 12, 120 Allergy 405 Alpha- fetoprotein 94, 419

Alpha error see type I error Alprenolol 474 Alternate allocation 446, 485, 494 Alternative hypothesis 165, 168 Altitude 503 Ambroxol 458 Ambulatory blood pressure monitoring 79 Amniocentesis 419 Anaemia 413 Analgesic 83, 430, 436 Analysis of covariance 309, 318, 339, 465 Analysis of data 3, 4, 5, 8, 38, 113- 14, 118- 19 choice of method 179- 80, 189 confirmatory 338 exploratory 113, 121, 174, 282, 298, 338, 359 relation to design 5, 179- 80, 426, 430 relation to type of data 10, 17, 180 strategy for 112- 14, 175- 6 Analysis of variance and linear regression 297, 308 and multiple regression 325- 6 multiple comparisons in 210- 13, 215 one way 205- 13, 221, 328, 333, 426 assumptions 182, 206 Kruskal- Wallis 213- 15, 265, 335 linear trend 212- 13, 215- 16, 219, 318- 19 mathematics 218- 20 non- parametric 213- 15, 265, 335 ordered groups 212- 13, 215- 16, 219, 318- 19 presentation of results 220- 2

Analysis of variance (cont.)

one way (cont.) using means and SDs 219 using raw data 219 residuals from 207, 330, 334 two way 325- 36 assumptions 330- 1, 334 Friedman's (non- parametric) 334- 6 goodness- of- fit 330 Angina 2, 7 Animal experiments 83, 90 Anova see Analysis of variance Anti- convulsant therapy 97 Anti- hypertensive treatment 50, 124, 125, 451, 458, 471- 2 Anti- smoking advice 357 Antibiotic 438 Antiemetic treatment 225 Antilogarithm 37, 62, 267, 401, 424, N511 Aortic valve disease 397, 400 Apgar score 15, 172, 180 and growth retardation 267 Arm circumference 80, 397 Area under the curve (AUC) 430, 431- 3 Arthritis, rheumatoid 45, 274- 5, 436, 465 Arthritis and Rheumatism 479 Ascertainment bias 95 Aspirin and hypertension in pregnancy 275, 476 and myocardial infarction 451 and pruritus 474 and stroke 451 Association 276 and agreement 284, 401 and causality 96, 102- 3, 247, 297- 8, 321, 467, 490 spurious 283, 285 see also Correlation Asthma 66, 466 in children 273- 4 in women 157, 162, 165, 230, 231, 232 Astronauts 223 Average 21- 2 Aviation accidents 19, 47

Azathioprine 148, 389- 90, 391

Babies, sex of 49, 71- 2, 177 Back- transformation 37, 38, 61, 202, 421 Back pain 38- 9, 77 Balanced design 80 Bar (e.g. x) 22, N509 Bar diagram 19, 24, 39 Bartlett's test 207- 8 Baseline characteristics 6, 38- 9, 90, 461- 2, 464- 5, 473 Batches 90 Bayes' theorem 415 Bed, hours spent in 274 Beer 101, 102 Berkson, J. 93 Berksons's bias 93 Beta- blocker 386, 471- 2, 474 Beta error see Type II error Betel chewing 275 Bias in analysis 386, 387 ascertainment 95 avoidance of 7 in design 7, 81, 93, 94, 96, 102 detection of 95 in method comparison 398, 402 prevention of 85- 6, 441, 494 publication 169- 70, 472- 3, 483 recall 94- 5 sampling 7 surveillance 99 volunteer 100, 446, 484 see also Clinical trial, bias in Bilirubin 60- 2, 136, 143, 148, 157, 164, 390, 392 Binary variable 10, 339, 351- 2, 359, 414, 458 Binomial distribution 63- 6, 68- 70, 155, 157, 186, 230, 231 Normal approximation to 66, 155, 157, 161, 186, 230, 231, 239, 459 for paired proportions 239- 40 and sign test 240 Bioavailability 432 Biopsy 359 Biotin 435- 6

Birth date of 446 month of 434 Birth sign 466 Birth weight 2, 6, 78, 98, 174, 319 centiles 425 and length of gestation 266, 310, 326, 425 and metabolic rate 322 and parental birth weight 337 piglets 142 Blinding 82 see also Clinical trial; Blindness Blindness (lack of sight) 442 Blood 90 Blood donors 413, 437 Blood group 49, 63- 6, 68- 9, 71 Blood pressure 2, 124, 125, 132, 146, 147, 173- 4, 284, 318, 397, 423, 451, 458, 475 circadian rhythm of 148, 433, 434 comparison of two arms 79- 82, 83, 84, 86, 90, 168, 333 measurement of 12, 146, 147 in pregnancy 426, 501 variability of 35, 72- 3, 78, 82 see also Hypertension Blood transfusion 419 Blood viscosity 288, 348- 9 Body fat percentage 278- 9, 282, 283, 286, 294, 298 mass index (BMI) 125 mass percentage (BMP) 342- 5, 347, 349 temperature 78 see also Height; Weight; Obesity Bone marrow transplantation 361, 395 Bonferroni method (correction) 211, 261, 329, 465 Box- and- whisker plot 33, 39, 62 Brackets N506- 7, N510 Bran 504 Bread consumption 43 Breast cancer 66, 89, 444 adjuvant chemotherapy for 452, 486 and the contraceptive pill 1 and positive nodes 89, 375, 382, 462

Breast cancer (cont.) recurrence of 269- 70 screening for 356- 7 type of treatment 365, 452, 489 British Medical Journal 465, 473, 488, 494 Caesarean section 102 and maternal shoe size 229, 261- 5, 319 Caffeine 98, 242- 4, 247- 8, 249, 265 Calculator 17, 35, 112, 175, 256 Cancer 94, 102, 393 advanced 447 breast see Breast cancer cervical 50, 95 and fluoride 1, 90 liver 96 lung 51, 91, 93 oral 275 recurrence 269- 70, 393 registrations 66 skin 272 Cannabis 103 Canonical variate 359 Captopril 475 Cardiac bypass surgery 207 Cardiovascular disease 7 Caries 438 Carrots 93 Case control study 50, 74, 76, 91, 93- 6, 102, 266, 268- 70, 494 ascertainment bias 95 matched 94, 189, 269 recall bias 94- 5 selection of cases 94 selection of controls 93- 4, 484 Categorical data 10- 11, 117, 123, 229 analysis of 229- 72 in multiple regression 339, 351 Causal link 91, 96, 102- 3, 247, 297- 8, 321, 467, 490 Censored observations 16, 22, 365, 369, 370, 378, 385, 394 Census 74 Centile 31- 3, 37, 58, 221, 358, 420- 1 confidence interval for 422- 3 Central cholestasis 390

Central limit theorem 154, 164, 173, 177, 181 Central range 33, 37, 57 Cervical osteoarthrosis 233, 252 Cervical smear 95 Change from baseline 430, 466 over time 101- 2 relation to initial value 284- 5 Checking results 114 Checklists 494- 7 for clinical trials 473, 491, 494, 496- 7 for general medical papers 495 Chemotherapy 225, 447, 452, 486 Chi squared  $(x^{2})$  distribution 214, 244- 6, 247, 248, 252, 259, 261, 335, 373, 381, 382, 383, N512 relation to Normal distribution 244- 6, 258 table of 523 Chi squared  $(x^{2})$  test 241- 65, 271, 467, 491 degrees of freedom 245, 246- 7 interpretation 247- 8 presentation 271 sample size 248, 253 for trend 261- 5, 319  $2\times 2$  table 249, 250- 3, 254, 257- 9, 260 equivalence to comparison of proportions 257- 8, 259, 271 Yates' correction 252- 3, 260  $2\times k$  table 259- 65 ordered groups 261- 5 unordered groups 259- 61  $k\times k$  table 266  $r\times c$  table 242- 4, 247- 9, 265 Chlorine 250- 2, 269 Cholesterol 2, 59, 165, 166, 285 Cigarettes 13, 351 see also Smoking Circadian variation 79, 148, 434 Circumferential shortening 300- 3, 306- 9, 310- 18, 320, 323 Cirrhosis 96, 297- 8, 390 see also Primary biliary cirrhosis Clinical importance 170, 297, 455- 6, 457, 461, 464

Clinical practice 5 Clinical research 8 Clinical trial 76, 102, 167, 440- 74 adaptive designs 449 adjusting for other variables 375, 464- 5 alternate allocation 446, 485, 494 analysis of 461- 71 assessment of 473- 4, 494 baseline characteristics 461- 2, 464- 5, 473 bias in 441, 442, 445, 446, 450, 461, 464, 469, 473, 483, 494 blindness 82, 88, 449, 450, 474, 494 checklist for 473, 491, 494, 496- 7 comparability of groups 461- 2, 464- 5, 473 comparison with uncontrolled study 441, 478 controls 446- 7, 480, 483 crossover see Crossover trial design 441- 55 diagnostic (entry) criteria 451- 2, 454, 460, 471, 485 double blind 450, 494 dropouts see Withdrawals eligibility criteria 451- 2, 454, 460, 471, 485 ethical aspects 449- 50, 451, 452- 3 exclusions 464, 485 historical controls 446- 7, 453 incomplete data 463 informed consent 449, 452, 454 intention to treat analysis 464 interpretation of results 442, 471- 3, 490 in medical journals 480, 482, 483 method of randomization 491, 494 minimization 443- 5 multi- centre 89, 443, 455, 460 multiple comparisons 453- 4, 465 non- randomized 443, 446- 7, 453, 483 outcome measure 16, 393, 453- 4, 462, 465- 6, 473, 487 parallel groups 447 phases I- IV 440, 442 placebo 450- 1, 452 protocol 454- 5, 466

Clinical trial (cont.)

protocol (cont.)

violation 454, 463- 4

pseudo- random allocation 446, 485, 494

random allocation 85, 91, 442- 3, 482, 491

randomization 442- 3, 454, 461, 462, 485, 491

block 443

simple 86- 7, 443, 444, 452, 464

stratified 88- 9, 443, 444, 450

weighted 87, 444, 459

sample selection 451- 2, 454, 460, 471, 485

sample size 443, 447, 452, 454, 455- 60, 464, 474, 484

sequential design 448- 9, 455

side effects 447, 451, 453, 454, 463

single blind 450

subgroup analyses 466- 7, 472, 473

systematic allocation 446, 485, 494

treatment allocation 86, 87, 442- 7, 450, 461, 485

withdrawals 447, 463, 471, 473

writing up 473

Clonixin 436

Cluster analysis 360

Cochran, W. G. 248

Coffee 102

Cohort life table 371

Cohort study 74, 91, 96- 9, 102, 480

historical 91

loss to follow up 98- 9

selection of subjects 97- 8

surveillance bias 99

Colitis, ulcerative 359

Combining  $2 \times 2$  tables 270- 1

Combining data from different studies 383, 472- 3

Community controls 94

Comparability of groups 39, 78, 81, 88- 9, 375, 442, 461- 2, 464- 5, 473

Comparative study 6, 485 see also Clinical trial

Comparison

of categorical assessments 405- 8

of distributions 31

Comparison (cont.)

of groups (categorical data) 160- 1, 229- 72

independent 232- 5, 241, 250- 8, 259- 65, 266- 9, 319

paired 235- 41, 258- 9, 266, 269- 70

of groups (continuous data) 189- 223, 326- 36

independent 191- 223, 318- 19

paired 189- 91, 222- 3

of methods of measurement 277, 284, 396- 403, 484, 486

of observers 397, 403- 9

of risks 266- 71

of survival 371- 6, 379- 85, 386- 7

of variances 197- 8, 206

Complex analyses 223, 285, 360

Compliance 463- 4

Computer

advantages 107- 8

availability vii, 479, 492

data input 114- 16, 122, 123

disadvantages 108- 10

graphics 40, 108, 119- 20, 125, 142, 149

misuses 120- 1, 479, 488, 492

package see Computer program

precision of calculations 17, 112

simulation 120, 155, 157

software see Computer program

strategy for statistical analysis 112- 14

use of 13, 38, 107- 21, 149, 175, 205

Computer monitor (VDU) 72, 77, 91, 95, 259- 61

Computer program

for analysis of variance 206, 208, 212- 13, 218

errors in 108- 9, 111

evaluation of vii, 110- 12

exact P value from 168, 171, 253

for Fisher's exact test 254, 256, 257

for linear regression 293, 302, 308, 310, 312, 320

for logistic regression 355

for Mann- Whitney test 196, 197, 265

missing data in 109- 10, 124, 130- 1

for multiple regression 344, 345, 348, 349

Computer program (cont.)

for random numbers 86

for rank correlation 288, 296

spreadsheet 112

for survival analysis 366, 370, 375, 377, 379, 389, 391

for  $t$  test 194

for testing Normality 149, 291, 303 types of 110

Conclusions 4, 7, 477, 482, 483

Conditional probability 368

Confidence interval 162- 5, 223

for correlation coefficient 279, 282, 288, 293- 4, 295, 297

for geometric mean 202

incorrect use 486, 487

for kappa 405, 406

for limits of agreement 402

for means and their differences 162- 4, 181, 183- 4, 190, 192- 3, 201- 2, 209- 10, 221, 222, 329

for medians and their differences 173, 185, 194

table for 535- 7

for odds ratio 269- 70

in papers 177, 486, 487, 489- 90, 498

for proportions and their differences 165, 230, 233, 235, 236- 7, 252, 253, 271, 369, 416

for regression coefficients 306,

313- 15, 316, 319, 320, 321, 336,

351, 354

preferable to hypothesis test 166, 169, 175, 473, 485

presentation of 176

relation to hypothesis test 175, 235, 240

for relative risk 267- 8

for survival time analyses 369- 70, 371, 376, 378- 9, 383- 5, 391

after transformation 199, 201- 2

Confidence limits see Confidence interval

Confirmatory analysis 338

Confounding 81, 402- 3, 484

Contingency table see Frequency table

Continuity correction

for Chi squared test 252- 3, 260

Continuity correction (cont.)

for comparison of proportions 231- 2, 235, 238- 9

for McNemar's test 258- 9

for sign test 187

Continuous data 12- 13, 40, 117- 18, 123- 4, 165, 272, 434, 457- 8

analysis of 179- 223, 277- 321, 325- 61

Contraceptives, oral 1, 50, 95, 105

Control group 77

in case control study 93- 4, 484

in clinical trial 446- 7, 480, 483

Controlled trial see Clinical trial

Coordinates N513

Coronary artery disease 363

Correlation 277- 300, 341, 344, 351, 401

for assessing non- Normality 291- 2

association and causality 247, 297- 8, 321

assumptions 279

coefficient 278, 299

distinction from regression 277, 320- 1

international 290- 1, 298

interpretation 297- 8, 318

Kendall's rank (r) 286

mathematics 293- 6

matrix 288, 299, 342

misuses 282- 5, 320- 1, 401- 2, 409, 489

mixed samples 283

partial 288- 91, 296, 297, 348- 9

Pearson's (product moment) (r)

278- 86, 288, 293- 4, 297, 346

confidence interval 279, 282, 293- 4, 297

hypothesis test 279, 282, 294, 320

table for 528- 9

presentation 299

rank 265, 279, 285- 8, 295- 6, 297

restricted sample 283

sample size 298

Spearman's rank  $(r_{s})$  286- 8, 295- 6, 297

confidence interval 288, 295

hypothesis test 287, 295- 6

table for 530

spurious 283, 285

Cotinine 226

Coulter counter 90

Count 11, 66, 143, 241see also Frequency

Covariance, analysis of 309, 318, 339, 465

Covariate 80, 389, 392see also Predictor variable

Cox regression 387- 93  $C_{p}$  345

Creatinine 145

Creatinine clearance 323

Crime 68

Crohn's disease 359

Cross- classification 229, 326see also Frequency table

Cross- sectional study 76, 92, 99- 101, 102, 480

cause or effect? 100- 1

response rate 100

sample selection 99- 100

volunteer bias 100

Cross- tabulation 229, 326see also Frequency table

Crossover trial

analysis 467- 71

baseline data 469- 71

carry- over effect 448, 469

design 447- 8, 467

period effect 448, 467, 469

treatment effect 469

treatment- period interaction 448, 467, 469

wash- out period 448, 469, 471

Croton oil 272

Cube N507

Cubic curve 425

Cumulative frequency 29- 31, 133

Cumulative relative frequency 29- 31, 54

# Curve

cubic 425

quadratic 310, 317, 319, 424

sine (sinusoidal) 434- 5

Cyclic variation 433- 5

see also Circadian variation; Seasonal variation

Cystic fibrosis 21, 50, 73, 97, 338, 347, 349

# Data

binary 10, 339, 351- 2, 359, 414, 458

categorical 10- 11, 117, 123, 229, 339, 351

analysis of 229- 72

censored 16, 22, 365, 369, 370, 378, 385, 394

checking 113, 122- 6, 149

cleaning 122- 6

collection 3, 114- 19, 485

continuous 12- 13, 40, 117- 18, 123- 4, 165, 272, 434, 457- 8

analysis of 179- 223, 277- 321, 325- 61

325- 61

description 19- 45

discrete 11, 63, 66

- dredging 120-1, 282

entry 113, 122- 3

nominal 11

ordinal (ordered categorical) 11, 180, 229, 249, 261- 5, 272, 319, 409, 434, 486

229, 249, 261- 5, 272, 319, 409, 434, 486

precision 487

presentation 18, 42- 5, 221, 271, 433

registries 484

screening 113, 122, 132- 43, 148, 149

transformation see Transformation of data

types of 10- 18, 180

see also Analysis of data; Distribution of data; Frequency; Proportion

Database 118

Dates 13, 118, 125- 6, 131

Death 393

age- specific rate 499

number per day 68

Decimal places 12, 42

Degrees of freedom 181, 192, 209, 245, 246- 7

Denominator 487, N507

Dental enamel erosion 250- 2, 269

Dental health 96

Dependent variable

in Cox regression 388

in linear regression 301

in logistic regression 352, 355

in multiple regression 340, 345, 346, 351

Derived variable 13, 108, 125, 131, 340, 429- 31 Describing data 19- 45, 152 Design 4, 5, 6, 74- 103, 402, 426, 480 balanced 80 choice of 102- 3 errors in 477, 482- 5 quality of 5 relation to analysis 5, 179- 80, 426, 430 structure of 83- 5 types of 75- 7 weaknesses in 84 Detection bias 95 Diabetes 2, 71 Diabetics 94, 172- 3, 177- 8, 300- 3, 310, 475 Diagnosis 3, 335- 7, 359, 413, 414, 417, 418, 419 see also Diagnostic test Diagnostic index 355 Diagnostic test 356, 409- 19, 420, 425, 483, 486, 494 based on continuous measurement 413- 14, 419 effect of prevalence 411- 13, 418 Diarrhoea 359 Diathermy, short wave 38 Dichloroacetate 321 Dichotomous variable 10 Dietary advice 6 Dietary intake 3, 95, 96 of energy 183- 5, 188, 189- 91 and menstrual cycle 189- 91 Diets 84, 333, 361 Differences see Comparisons Digit preference 146- 8 Digoxin 323 Dinitrochlorobenzene (ONCB) 272 Discrete data 11, 63, 66 Discriminant analysis 355, 358- 60 Discriminant function 359 Discrimination 355- 60, 413, 414 Distribution- free methods see Non- parametric methods Distribution assumption about 51, 58, 143, 171- 2, 174, 189, 486

Distribution (cont.) asymmetric 136 bimodal 53 Binomial see Binomial distribution of data 29- 31, 33, 38, 51, 132- 3, 173, 180, 279 empirical 51, 420 exponential 385 F see F distribution frequency 23, 29- 31, 54, 133 Lognormal 60- 3, 143, 164, 392, 420 Normal see Normal distribution Poisson 66- 8, 70- 1, 145, 246 probability 50- 1 of sample means 154- 7, 177, 181 sampling see Sampling distribution shape of 38, 136, 194 skewed (asymmetric) 36- 8, 53, 59, 60- 3, 136, 145, 157, 172, 185, 199- 205, 221- 2, 392, N510 symmetric 36, 53, 61, 133, 154, 188, 204- 5, 222, 299 t see t distribution tails of 36, 58, 139, 166- 7, 171, 181, 255, 257, 421 theoretical 50- 71, 171, 175 Uniform 71, 120, 146 unimodal 53, 154 see also Normal distribution of data Division N507 Dizygotic twinning rate 288- 90, 295, 296 Doctors 451 Double dummy technique 450 Down's syndrome 94, 419 Drop outs see Withdrawals Drugs 3, 90 users 437 Dual photon absorptiometry 279 Dummy variable 339, 392 Duncan's multiple range test 211 Duodenal ulcer 441

e N510 e\* N511 Echocardiography 300, 397 Effect of interest 83, 165, 166, 169, 455

Eggs 1, 436 Ejection fraction 149 Electrocardiograph 2 Eligibility criteria see Sample selection Emesis 368 Empirical distribution 51, 420 Employment 100 Enalaprilat 328 Endometriosis 227 Endpoint see Clinical trial, outcome measure Energy expenditure 193- 4, 197 intake 183- 5, 188, 189- 91 Envelopes 88, 89, 450, 485 Epidemiological study 8, 75, 91, 102, 266, 268, 297, 352, 355, 396, 478 Error bars 426 Errors in analysis 261, 385- 7, 401- 2, 426- 7, 477, 482, 486- 7 of omission 7, 474, 482, 490- 1 rounding 17, 71, 312 statistical see Statistical errors in papers transcription 122- 3, 124, 125 Type I 169, 211, 457- 9, N511 Type II 169, 457- 9, N512 Estimate 153, 174- 5, 176 precision of 80, 83, 175, 465, 487 uncertainty of 153, 154, 157, 160, 162- 5, 175 see also Confidence interval Estimation 160- 5, 223 and hypothesis testing 166, 174- 5, 271, 397 Ethics 477- 8, 491 of clinical trials 449- 50, 451, 452- 3 committee 453, 454, 491, 492 Exclusion criteria see Sample selection Expected frequency 243- 4, 246, 247, 248, 250- 1, 253, 254, 256, 404, 406 Experiments 74, 75- 6, 102, 325 clinical (trials) 440- 74 design of 80- 5 laboratory 8, 90, 318 Explanatory variable see Predictor variable

Exploratory analysis 113, 121, 174, 282, 298, 338, 359 Exponential distribution 385 Exposure 91, 374 Extrapolation 6, 7, 100, 152, 317 Eye sight 254- 7 strain 77, 259- 61

$F$  distribution 197, 206, 209, N513 relation to t distribution 207 table of 524- 7  $F$  test 197, 206, 207, 211, 219- 20 Factor 83, 326 Factor analysis 360 Factorial (!) 70, 256, N509, N513 Factorial design 84 Factorial trial 449 Failure time see Survival time False negative findings 169, 414, 418, 419 rate 415 False positive 357 findings 169, 211, 414, 418, 419 rate 415 Febrile seizure 97 Fetal growth 267, 425 Fetal movements 77 Fetus 419, 423 abdominal area 319 head curcunference 101, 331- 3 scalp blood pH 422 ultrasound 484  $\mathbf{FEV}_{1}$  345, 347 Fibre 287, 298 Fibrinogen 288, 348- 9 Figures see Graphs File 113, 118- 19 Fisher, R. A. 253- 4 Fisher's exact test 253- 7 Fluoridation of drinking water 1, 90, 500 Folate 207, 210, 211- 12 Follow up duration of 393 loss to see Withdrawals study 96- 9

Forced expiratory volume  $\mathbf{(FEV_{1})}$  345, 347 Form, data collection 114- 19, 454 design 116- 18 Format for data input 114- 16 Frequency 23, 229, 241, 434 cumulative 29- 31, 54, 133 distribution 23, 29- 31, 54, 133 expected 243- 4, 246, 247, 248, 250- 1, 253, 254, 256, 404, 406 histogram see Histogram observed 243, 246, 248, 253, 406 polygon 27, 52- 3 relative 27, 29, 51 table 229, 241- 66 multi- way 360  $2\times 2$  249, 250- 9, 260, 266, 269, 270- 1, 379  $2\times k259 - 65$ $k\times k266$ $r\times c242 - 4,247 - 9,265$  Friedman's two way analysis of variance 334- 6 Function N510 Functional residual capacity (FRC) 361

Gastric freezing 441 Gauss, C. F. 51 Gaussian distribution see Normal distribution Gender of baby 49, 71- 2, 177 General practice 7 General practitioner (GP) age- sex register 7 referral 99 Geometric mean 22, 37- 8, 62, 164, 202 Gestational age 42 and birthweight 266, 310, 326, 425 Gestrinone 227 Glasses (spectacles) 216, 254- 7 Globulin 288 Glucose 172- 3, 177- 8, 292, 300- 3, 306- 9, 310- 18, 320, 323 Goodness- of- fit 174 see also under specific methods Gossett, W. S. 181 Graft versus host disease (GvHD) 361, 395

Graphs 16, 43- 5, 221, 369, 397, 400, 402, 418, 426 error bars in 221, 426 misleading 488- 9 in scientific papers 488- 9 see also specific types of graph Greenwood, M. 379 Greenwood's standard error 379 Group sequential trial 449 Groups, comparability of 39, 78, 81, 88- 9, 375, 442, 461- 2, 464- 5, 473 Growth chart (standard) 425 retardation 267 versus size 101 Guidelines see Statistical guidelines

Haematocrit 288, 348 Haemodialysis 226 Haemoglobin 90 Handedness 2, 103, 105 Hat (e.g. p) N509 Hazard 388, 390- 1 function 388, 392 ratio 375- 6, 383- 4, 385, 390 Head circumference 101, 331- 3 Headache 165, 214 Health 2 education 90, 99 of juvenile deliquents 254 Healthy worker effect 484 Hearing 75 Heart attack 2, 357 disease 2, 7, 51, 358 and snoring 264 valvular 363 failure 149, 323, 327- 8 - lung transplantation 364 rate 223, 327- 31 volume 396 Height 49, 59, 146, 336, 350, 351 of adults 51, 71, 72, 499 of children 125, 457 gain 457 Helicopter 334- 6 Heparin 226 Hepatitis, chronic active 178

Hill, A. Bradford 478, 492 Histogram 23- 8, 33, 36- 7, 39, 43, 51, 52, 60, 113, 133 relative frequency 27, 29 Historical controls 446- 7, 453 HIV seropositivity 413, 416, 419 Hodgkin's disease 126, 150, 200- 5, 225 Homogeneity of variance 143, 180, 192, 197- 8, 199- 201, 206, 303 Hormones 434 Hospital 6, 177 admission rates 93 controls 93 notes 114, 122, 132 numbers 446 HTLV- III antibody 413 Hypertension 79, 132, 352- 6, 413, 425 in pregnancy 275, 476 see also Blood pressure Hypothesis test 165- 71, 174 alternative hypothesis 165, 168 errors, types I and II 169, 211, 457- 9 inappropriate use 397, 403, 461, 486 interpretation 167- 9, 177, 222- 3, 429, 485, 489 multiple tests 211, 453- 4, 465 null hypothesis 165- 7, 168, 170 presentation 175, 176- 7, 220, 221, 487 relation to confidence interval 175, 235, 240 and sample size 167, 169, 455- 9, 485 significance level 168, 344- 5 two- sided or one- sided 170- 1, 177, 214 see also P value; Power; Statistical significance Hypothyroid infants 198

IgE 405, 434, 435 IgM 23- 4, 27, 28, 31- 3, 36, 38, 41, 51, 53, 59, 420- 1, 423- 5 Imbalance 88- 9, 375, 442, 461- 2, 464- 5 Immersion suits 334- 6 Imprecision see Precision Inaccurate recall 94- 5 Inclusion criteria see Sample selection Independence 49- 50, 350

Independent groups 180 Independent observations 230, 282, 318 Independent variable see Predictor variable Inference, statistical 5, 71, 169, 490 see also Sample, as estimate of population Infinity N510, N513 Inflammatory bowel disease 359 Infra- red stimulation (IRS) 233- 5, 252- 3 Input format 114- 16 Intention to treat analysis 464 Inter- observer variation see Observers Inter- quartile range 33 Inter- rater agreement see Observers Interaction 330, 331, 351, 354, 449, 467 Intercept 302, 312, 315, 316, 320 International correlation 290- 1, 298 Interpolation 33, 38 Interpretation of results 5, 8, 81, 94, 174, 177, 337, 442, 471- 3, 482, 489- 90 Intervention study 152 Irritable bowel syndrome 504 Ischaemic heart disease 7, 358

Journal of the American Medical Association 465 Journals see Medical journals Juvenile delinquents 254- 7

Kaplan- Meier survival curve 368- 71, 377- 9, 384, 385, 386, 394 Kappa 404- 8 confidence interval for 405, 406 interpretation 407- 9 weighted 406, 407 Kendall, M. G. 286 Kendall's tau (t) 286 Kidney transplant 124, 145, 360 Knee circumference 401 Kruskal- Wallis test 213- 15, 335 ordered groups 215- 16, 265 Kurtosis 136

Laboratory experiment 8, 90, 318 Lack of fit see Goodness- of- fit

Lactic acidosis 321, 394

Lancet 465, 478, 488

Latitude 288- 90, 295, 296

Least squares method 301

Left- handedness 2, 103, 105

Left ventricular stroke volume (SV) 397- 400

Leukaemia 1, 3, 362

Lie- detector 437

Life events 269- 70

Life table 368, 371, 394

Likelihood ratio 417

Limits of agreement 399- 400, 402

Linear analogue scale 15- 16, 172

Linear model 173

Linear regression 126- 7, 213, 219, 262, 277, 299- 321, 326, 336, 337, 402, 423, 430

analysis of variance table for 297, 308, 316

assumptions 303

confidence intervals 320, 321

for estimate 314- 15

for line 306- 7, 314- 15, 316, 319, 320

320

for slope 306, 313, 319, 320

dependent variable 301

distinction from correlation 277, 320- 1

explanatory variable 301, 303, 317

extrapolation 316- 17

fitted values 301, 312, 314

goodness- of- fit 302- 6, 308

hypothesis tests 315- 16, 319, 320

independent variable 301, 303, 317

intercept of line 302, 312, 315, 316, 320

interpretation 316- 18

least squares principle 301

line 301- 3, 306, 310- 12

mathematics 310- 16

non- parametric 318

outcome variable 301

prediction interval 307, 315, 316, 319, 320, 321

predictor variable 301, 303, 317

presentation of 319- 20, 487- 8

$R^{2}$  308

Linear regression (cont.)

residual 301, 303- 6, 308, 313, 423

residual standard deviation 308, 313, 319, 320

residual variance 302, 308, 313

response variable 301

slope of line 262, 302, 306, 309, 311- 12, 315, 316, 319, 320, 430

standard error 306, 314- 15, 319

two samples 309, 339

variation explained 308- 9, 316

Linear relation 279, 296, 300, 303

Linear transformation 41

Linear trend

for categorical data 249, 261- 5, 319, 339

for continuous data 212- 13, 215- 16, 220, 318- 19, 339

Liver

biopsy 66

scan 409- 11

transplantation 368

see also Cirrhosis; Primary biliary cirrhosis

Log- linear model 272

Log odds 352

Logarithm 36, N510, N511

Logarithmic transformation 36- 7, 41- 2, 60- 2, 126, 136, 143- 5, 199, 200- 3, 205, 287, 303- 6, 392, 400- 1, N510

$\log_{e}x$  N510, N511

Logical check 124- 5

Logistic regression 146, 326, 351- 8, 359 coefficient 354, 358

computing 355

confidence interval 354

dependent variable 352, 355

for discrimination 355- 8, 413, 414

explanatory variable 352, 355

goodness- of- fit 358

prognostic index 355

prognostic variable 355

stepwise 355

Logit transformation 145- 6, 352

Lognormal distribution 60- 3, 143, 164, 392, 420

Logrank test 371- 5, 379- 83, 385, 386, 394

Logrank test (cont.)

for trend 374- 5, 381- 2

stratified 375, 382- 3

Longevity 2, 103, 105

Longitudinal study 76, 96- 9, 466

Loss to follow up see Withdrawals

Low back pain 38- 9

Lower respiratory tract infection 438

Lung capacity 364

Lung function 21, 351, 466

see also  $\mathbf{FEV}_{1}$ ; PEmax; PImax

Lung transplantation 364

Lymphocyte abnormalities 200

Main effect 354

Mammals 279

Mammography 356- 7

see also Xeromammogram

Mann- Whitney (- Wilcoxon) test 194- 7, 198, 213, 214, 215, 265, 467

table for 532- 4

Mantel- Haenszel method 271

Marijuana 236- 9

Marital status 242- 4, 247- 8, 339

Mastectomy 76, 452

Matching 94, 180, 189, 448, 491

Mathematical notation 9, N505- 13

Matrix

correlation coefficients 288, 299

scatter plots 342

Maximal static expiratory pressure (PEmax) 336, 339, 341, 342- 5, 347, 350

Maximal static inspiratory pressure (PImax) 21- 2, 23, 28, 35, 40, 109

Maximum likelihood 355

McNemar test 240, 258- 9, 266, 416

Mean 21, 33, 37, 38, 41, 171, 221, 222, 423- 4, 430, N506

confidence intervals for 162- 4, 181, 209- 10, 221, 222, 329

single sample 183- 4

two paired samples 190, 201- 2

two unpaired (independent)

samples 192- 3

geometric 22, 37- 8, 62, 164, 202

Mean (cont.)

hypothesis test for

several samples 206- 9

single sample 184- 5

two paired samples 191

two unpaired (independent)

samples 194

presentation of 42, 487, 488, 489

sampling distribution of 153- 7, 177, 181

square 209

standard error of see Standard error

Media reporting 1, 2, 3, 90

Median 22, 33, 37, 38, 42, 164, 173, 221, 487

confidence interval for 185, 194

Medical journals vii, 3, 4, 102, 465, 472, 477, 479- 91, 492- 3, 498

policy 42, 168, 175, 387, 478, 489- 90, 492, 493

role 493

see also Papers, scientific

Menarche, age of 287, 298

Menopause 89, 105

Menstrual cycle 189- 91, 434

Meta- analysis 270- 1, 472- 3

Metabolic rate 322, 333- 4, 361

Method comparison studies 277, 284, 396- 403, 484, 486

396- 403, 484, 486

bias 398, 402

design of 402

erroneous analyses 284

sample size 402

Migraine 83, 214

Milk consumption 288- 90, 296, 457

Minimization 91, 443- 5

Miscarriage 72, 91, 95

Missing data/value 109, 113, 115- 16, 118, 123, 124, 130- 2, 149, 326, 426, 429, 431, 433, 463, 484, 485

118, 123, 124, 130- 2, 149, 326, 426, 429, 431, 433, 463, 484, 485

429, 431, 433, 463, 484, 485

Mode 22

Model 171, 174, 317, 340, 349- 50, 352, 356- 7, 430

356- 7, 430

see also Regression

Moments 136

Month of birth 434

Moon 68

Mortality, perinatal 14, 19

Motion sickness 368, 372, 375, 379, 380, 384, 385, 394

Motoring accidents 101

Mountain sickness 503

Multi- RAST (MAST) 405- 7, 409

Multi- way frequency table 360

Multicentre study 89, 375, 443, 455, 460

Multiple comparisons 210- 12, 215, 248, 261, 329, 336, 387, 465, 491

Multiple correlation coefficient 346

Multiple counting 466, 486

Multiple logistic regression see Logistic regression

Multiple regression 309- 10, 326, 333, 334, 336- 51, 414, 465, 467

adjusted  $R^2$  345- 6, 351

adjusted  $R^2$  345- 6, 351

all subsets 345, 349

analysis of variance table for 343

assumptions 350- 1

coefficients 336- 7

confidence interval 336, 351

constant 336

dependent variable 340, 345, 346, 351

explanatory variable 336- 7, 339- 46, 348, 349- 51

fitted values 347- 8, 351

goodness- of- fit 345- 6, 349, 351

interpretation 337

model 336, 340- 7

overfitting 341, 345

prediction interval 351

predictor variable 336- 7, 339- 46, 348, 349- 51

presentation 351, 489

prognostic index 337, 347- 8

prognostic variable 336- 7, 339- 46, 348, 349- 51

$R^2$  345- 6, 350, 351

relation to analysis of variance 325- 6

relation to partial correlation 348- 9

residuals 341, 344, 346- 7, 349, 351

residual standard deviation 346, 351

sample size 349

standard error 336, 347

stepwise 340- 5, 349- 50

variation explained 340, 347

Multiple testing 338, 349, 371, 429, 433, 453- 4, 465, 486

Multiplication N506

Mustine 444

Myocardial infarction 94, 96, 97, 161, 386, 451, 464, 466, 474

N N510, N512

Nausea 225

Negative predictive value 410- 13, 415- 16, 419

Negative result 170, 489

Neural tube defects 446, 447

New England Journal of Medicine 102, 465, 479, 480

Newman- Keuls test 211

Nicardipine 467, 469

Nicotine chewing gum 459

Nitrous oxide 207

Nodes, positive 89, 375, 382, 462

Noise, loud 276

Nominal data 11

Nomogram 456- 60

Non- linear transformation 41

Non- linear trend 213, 296- 7, 310, 350

Non- Normal distribution 136- 42, 185, 306

Non- parametric methods 51, 130, 133, 145, 171- 3, 180, 189, 199, 207, 223

145, 171- 3, 180, 189, 199, 207, 223

for categorical data 265, 266, 271

for continuous data 199, 203- 5, 213- 16, 365

for correlation 279, 285- 8

for cyclic data 434

for reference range 423

for regression 318

for survival data 371- 5, 379- 83

see also specific methods

Non response 98, 100

Non- significant see Statistical significance

Nonsteroidal antiinflammatory drugs (NSAID) 465

Normal approximation 173, 196, 197

to Binomial distribution 66, 155, 157, 161, 230, 231, 239, 370, 459

to Chi squared distribution 244- 6, 258

to Poisson distribution 66, 246

Normal distribution 51- 60, 71 in analysis of variance 330, 334 of data 132, 172, 174, 180, 182, 199, 206, 223, 279, 330, 359, 457, 490 random samples from 60, 120, 153, 155- 7 and reference range 420- 1, 423, 425 in regression 303- 6, 318, 346 as sampling distribution 154, 162, 165, 166- 7, 173, 177, 181, 231, 233, 267 standard 54, 244, 258, 421 relation to  $t$  distribution 181 tables of 515- 20 testing for 133- 43, 166- 7, 207, 279, 291- 2, 303- 6, 346, 421 transformation to 61- 3, 133- 6, 143- 5, 199, 207, 421, N510 Normal plot 133- 43, 149, 207, 279, 291- 2, 303, 346, 347, 421 Normal probability paper 142 Normal range see Reference range Normal score 54, 142- 3, 292, 353, 425 Normality, test of 133- 43, 166- 7, 207, 279, 303- 6, 346, 421 Notation 9, N505- 13 Nuclear power installation 1 Null hypothesis 165- 8, 170 Number of subjects see Sample size Numerator 487, N507 Numerical precision 17, 18, 70- 1, 487- 8 Obesity 193, 194, 413 and hypertension 352- 5 Objective of research 120, 180- 1, 430, 454 Observation see Data Observational study (survey) 6, 74, 75- 6, 91- 3, 99- 101, 102- 3, 152, 325, 336, 370, 426, 467 Observers comparison of 397, 401, 403- 9 variation among 402- 3, 419, 438 Occupation 19 Ocular exposure 216 Odds 268, 352, 417 log 352 post- test 417 pre- test 417

Odds ratio 146, 268- 71, 352, 354 for combining  $2\times 2$  tables 271 confidence interval 269- 70 in logistic regression 352- 4 paired samples 269- 70 relation to relative risk 271 two independent samples 268- 9 Omission of information 7, 474, 482, 490- 1 One- sided (one- tailed) test 170- 1, 177, 214 Open study 441 Opinion poll 1 Oral contraceptive 1, 50, 95, 105 Ordinal (ordered categorical) data 11, 180, 229, 249, 261- 5, 272, 319, 409, 434, 486 Osteopathy 38 Outcome measure see Clinical trial, outcome measure Outliers 113, 126- 30, 139, 145, 149, 342, 346 Over- fitting 341, 345 Over- optimism 349, 351, 442 Overview 270- 1, 472- 3 Ovulation 360 Oxygen 442

P value 166, 175, 271, 344, 345, 465, 473, 485, 498, N511, N512 adjusted 221 comparison of 467, 486 exact 168, 171, 176, 196, 253 interpretation 167- 9, 177, 222- 3, 429, 485, 489 limitations 174- 5 over- reliance 169- 70 presentation 175, 176- 7, 220, 221, 487 two- sided or one- sided 170- 1, 177, 214 see also Hypothesis test; Statistical significance Packed cell volume (PCV) 288, 348 Pain 16, 38- 9, 233- 5, 441 Paired data 180, 486, 490 see also Comparison of groups

Papers, scientific 4, 7, 454, 455, 477- 99 assessing 177, 473- 4, 480, 481- 92, 494 checklists for 494- 7 confidence intervals in 177, 486, 487, 489- 90, 498 errors in see Statistical errors in papers figures in 488- 9 Methods section 7, 454 presentation of results 18, 176- 7, 220- 2, 471 reading 493- 7 refereeing of 478, 492, 493, 494 reviews of 455, 465- 6, 473, 479- 91 statistical guidelines for 494, 498 statistical methods used in 174, 479- 80 writing 471, 473, 498- 9 see also Medical journals; Presentation of statistical material Parallel groups 447 Parameter 51, 54, 171, 181 Parametric methods 51, 58, 143, 145, 171- 2, 173, 180, 181, 189, 223, 288, 421, 423, 425 see also specific methods Partial correlation 288- 91, 296, 297, 348- 9 relation to multiple regression 348- 9 Participation rate see Response rate Passive smoking 91 PBC see Primary biliary cirrhosis PCV see Packed cell volume Peak expiratory flow rate 82, 397 Peak value 430 Pearson, K. 278 Pearson's product moment correlation coefficient (r) see Correlation coefficient Pediatrics 479 PEmax 336, 339, 341, 342- 5, 347, 350 Percentage 13, 271, 487 Percentile see Centile Perinatal mortality 14, 19 Phenobarbitone 470 pH 145, 422 Piglets 142

Pilot study 460 PImax 21- 2, 23, 28, 35, 40, 109 Placebo 450- 1, 452 Placebo effect 451 Planning a study 75, 483, 484 Plethysmography 364 Pleural effusions 444 Plotting data see Graphs Poisson distribution 66- 8, 70- 1, 145, 246 Polygraph 437 Polynomial regression 310 Population 5, 50 see also Sample Pork 297 Positive predictive value 410- 13, 415- 16, 419 Positive result 170, 489 Posterior probability 416 Power 169, 170, 261, 450, 465, 469 and sample size 169, 170, 189, 393, 455- 60, 474, 484- 5 Powers N507- 8 Pre- eclamptic toxaemia 476 Precision of data 487 of estimates 80, 83, 465, 487 numerical 17, 18, 70- 1, 487- 8 spurious 42, 121, 487- 8 Prediction 277, 340, 410 see also Regression Prediction interval 307, 315, 316, 319, 320, 321 Predictor variable in Cox regression 388, 389, 392 in linear regression 301, 303, 317 in logistic regression 352, 355 in multiple regression 336- 7, 339- 46, 348, 349- 51 Prednisolone 178, 273- 4 Pregnancy 95, 101, 124, 423, 484 blood pressure in 426 hypertension in 275, 476 uric acid in 39 weight gain in 6 Presentation of statistical material 3, 494 analysis of variance 220- 2 Chi squared test 271

# Presentation of statistical material (cont.)

comparison of proportions 271 confidence intervals 176- 7

correlation 299

data 18, 42- 5, 221, 271, 433

hypothesis tests 175, 176- 7, 220, 221, 487

mean 42, 487, 488, 489

misleading 453- 4, 487- 9, 491

regression 319- 20, 351, 487- 8, 489

results 18, 176- 7, 220- 2

standard deviation 42, 222, 487, 488, 490

standard error 221- 2, 487, 488, 490

survival analysis 393- 4

t test 220- 2

see also Graphs

Prevalence 407, 411, 412, 413- 14, 415- 16, 418- 19, 423

Priests 101

Primary biliary cirrhosis (PBC) 52, 54,

60- 1, 136, 148, 155, 157, 160, 164, 166, 389, 391, 392, 393

Prior probability 416

Prison 101

Probability 48- 50, 53, 57, 69, 257- 8, 354, 356, 417

354, 356, 417

conditional 368

density 53

distribution 50- 1

in hypothesis tests see P value

prior 416

posterior 416

Product (II) N509

Product moment correlation coefficient see Correlation coefficient

Progesterone 426, 431, 433

Prognosis 389, 391, 413, 414, 442, 451, 465

Prognostic index 337, 347- 8, 390- 1, 414 see also Risk score

Prognostic variable 91, 375, 382, 448, 461- 2, 473

see also Predictor variable

Proportion 66, 154- 5, 157, 229, 352, 358, 434, N506

several samples 241, 259- 65, 319

single sample 230- 2

Proportion (cont.)

standard error of see Standard error transformation of 145- 6. 352

two paired samples 235- 41. 258- 9. 269- 70

two unpaired (independent) samples 232- 5, 250- 8, 259- 65, 266- 9

equivalence to Chi squared test

257- 8, 259, 271

see also Logistic regression: Survival time data, survival proportion

Proportional hazards regression 387- 93

Prospective study 74, 76. 266

Protocol 146, 454- 5. 463- 4. 466. 485

Pruritus 470- 1, 474

Pseudo- longitudinal study 76. 101

Pseudo- random allocation 446, 485. 494

Psychiatric patients 101

Publication bias 169- 70, 472- 3. 483

Pulmonary tuberculosis 440, 478

Quadratic curve 310, 317, 319, 424

Qualitative data see Categorical data

Quality control 149

Quantile 133

see also Centile

Quantitative data see Continuous data

Quartile 34

Questionnaire 98, 100

r see Correlation coefficient

$R^{2}$  308, 345- 6, 350, 351

adjusted 345- 6. 351

Radioallergosorbent test (RAST) 405- 7, 409

Radiologists 403- 4

Random

allocation 85- 90, 442- 3. 482, 491

numbers 86, 120, 285

computer generation of 86, 120

table of 540- 4

sample 6, 60, 82, 153, 155- 7, 279, 283

variation 19, 78, 316, 329, 472

Randomization 79, 80, 81- 2

block 87- 8, 89

cluster 90

restricted 87

simple 86- 7, 89

# Randomization (corr.)

stratified 88- 9 weighted 87 see also Clinical trial, randomization Range 31, 221 central 33, 57 checking 124, 149 inter- quartile 33 normal/reference see Reference interval Rank 13, 22, 33, 173, 185, 205, 213- 14, 286, 365 Rank correlation 265, 279, 285- 8, 295- 6, 297 Rank methods see Non- parametric methods Rank sum test see Wilcoxon test Rate 14 Ratio 14, 202 Raynaud's phenomenon 467 Recall bias 94- 5 Receiver operating characteristic (ROC) curve 417- 18 Reciprocal N508 transformation 141- 5 Rectal biopsy 359 Red cell volume 435 Refereeing 478, 492, 493, 494 Reference interval 76, 419- 26 confidence interval for 422- 3, 425 relation to age 423- 6 sample selection 420, 426 sample size 420, 422, 425 using empirical (per)centiles 420, 421- 3, 425 using Normal distribution 420- 3 using transformation 420- 1 Reference range see Reference interval Regression distinction from correlation 277, 320- 1 linear see Linear regression logistic see Logistic regression multiple see Multiple regression polynomial 310 presentation of 319- 20, 351, 487- 8, 489 for survival data see Cox regression to the mean 285

Relating a part to the whole 285 Relative frequency 27, 29, 51 Relative risk 266- 8, 271 Relaxation response 214 Reliability of results 4, 81 Renal failure 127, 226 Repeatability 401, 402, 419 Repeated measurements 80, 327- 31, 434 Replicate observations 82, 217, 331- 3, 401 Representative sample 6, 75, 78, 82, 100, 153, 160, 368, 451, 490 Reproducibility 331- 3 Research controversies in 3, 5, 96, 102 steps in 5 validity of findings 4 Residual in analysis of variance 207, 328, 330, 334 in linear regression 301, 303- 6, 308, 313, 423 in multiple regression 341, 344, 346- 7, 349, 351 Residual plot 303- 6, 346- 7, 351 Residual standard deviation 209, 221, 308, 313, 319, 320, 346, 351 Residual variance 207, 302, 308, 313, 329, 330 Residual variation 328 Respiratory muscle strength 22, 336 rate 438 tract infection 438 Response rate 7, 490 Response to treatment 387 Response variable 301 Resting metabolic rate (RMR) 322, 361 Results contradictory 3, 5, 96, 102 checking 114 interpretation of 5, 8, 81, 94, 174, 177, 337, 442, 471- 3, 482, 489- 90 presentation of 18, 176- 7, 220- 2, 271, 393- 4 Retrolental fibroplasia 441- 2 Retrospective study 74, 76, 91, 484

Reviews of the literature 455, 465- 6, 473, 479- 91

Rheological studies 485

Rheumatoid arthritis 45, 274- 5, 436, 465

Rifampicine 470

Risk 354

see also Relative risk

Risk factors 95

see also Prognostic factors

Risk ratio see Relative risk

Risk score 357

see also Prognostic index

Road accident casualties 24- 6, 101

Robustness 197

ROC curve 417- 18

Rounding 17, 18, 71, 312

Royal Statistical Society 478- 9

Running a mile 317

Runts 142

Salmonella 1

Salt 223

Sample 5, 223

biased 7

as estimate of population 5, 6, 8, 34, 50, 152, 157, 160, 451, 471

random 6, 60, 82, 153, 155- 7, 279, 283

representative 6, 75, 78, 82, 100, 153, 160, 368, 451, 490

Sample selection 6, 82- 3, 425, 426

see also Clinical trial, eligibility criteria

Sample size

for clinical trial 443, 447, 452, 454, 455- 60, 464, 474, 484

for comparing proportions 187, 189, 248, 253

for correlation 298

for discriminant analysis 359

and hypothesis test 167, 169, 455- 9, 485

inadequate 170, 455, 484

in multiple regression 349

as part of design 6, 83, 443, 455- 60, 464, 485

Sample size (cont.)

and power 169, 170, 189, 393, 455- 60, 474, 484- 5

and reference interval 420, 422, 425

and sampling distribution 143, 154, 161, 181, 248, 253, 378

in survival analysis 376, 378, 386, 393

unequal 459- 60

Sampling distribution 153- 9, 162, 171, 173, 177, 197, 230, 233, 354

and sample size 143, 154, 161, 181, 248, 253, 378

and sample size 143, 154, 161, 181, 248, 253, 378

248, 253, 378

Sampling unit 431, 466

Sampling variation 136, 155, 167, 170, 422

Scatter plot/diagram 40, 43, 113, 125, 133, 279, 299, 319, 342, 397, 469, 488, 489

Scheffé, H. 211

Schizophrenia 103

Scientific papers see Papers, scientific

Scores 14, 15, 172, 413

of ordered groups 215- 16, 262, 264- 5, 318, 339

264- 5, 318, 339

Screening 414, 418- 19

for breast cancer 366- 7

for cervical cancer 95

SD see Standard deviation

SE see Standard error

Seasonal variation 71, 148, 434

Seat belts 101, 162, 165

SEE 320

Selection of subjects see Sample selection

Selection of variables 337, 340- 5, 359, 389

SEM 160

Sensitivity 410, 412, 413, 415- 16, 418, 419

Sequential trial 448- 9, 455

Serial measurements 125, 331, 426- 33, 434, 489

area under the curve (AUC) 430, 431- 3

graphical display 426, 431

interpretation 433

problems with usual approach 426- 7, 433

Serial measurements (cont.) summary measures 429- 31, 433 Sex of baby 49, 71- 2, 177 Shapiro- Francia  $W^{\prime}$  test 139, 291, 303- 6, 330 table for 538- 9 Shapiro- Wilk  $W$  test 139, 166, 279, 291 Shoe size 229, 261- 5, 319 Siblings, sex ratio of 273 Sign test 186- 7, 204, 205, 240, 336 Significance level  $(\pmb {\alpha})$  168, 344- 5 Significance test see Hypothesis test Significant see Statistical significance Significant figures (digits) 320 Simulation 120, 155, 157 Singing voices 273 Sinusoidal (sine) curve 434- 5 Size of sample see Sample size Size versus growth 101 Skewness 36- 8, 136 see also Distribution, skewed Skin problems 474 Sleeping difficulties 236- 9 Slope of regression line see Linear regression Smoking 2, 7, 95, 96, 357, 459 and cancer 93, 275 and hypertension 352- 5 passive 91 and tooth eruption 31 and urinary cotinine excretion 226 see also Cigarettes Snoring and heart disease 264 and hypertension 352- 5 Social class 7 Sodium aurothiomalate (SA) 45, 274- 5 Software see Computer program Space deconditioning 223 shuttle 223 Spearman, C. 286 Spearman's rank correlation coefficient  $(r_{s})$  286- 8, 295- 6, 297 table for 530 Specificity 410, 412, 413, 415- 16, 418, 419, 420 Spectacles (glasses) 216, 254- 7

Sphygmomanometer 79, 148 Spreadsheet 112 Square N507 Square root N508 Square root transformation 41, 143, 145, 202 Stage of disease 12, 96, 172, 375 Standard deviation (SD) 33- 6, 37, 38, 41, 42, 153, 154, 155, 171, 181, 398, 422- 4, 457, N506 presentation of 42, 222, 487, 488, 490 similar in different study groups 143, 180, 192, 197- 8, 199- 201, 206 see also Variance Standard deviation score 425 Standard error (SE) of centile 422 of difference between means 160- 1, 190, 192 of difference between proportions 162, 233, 234, 237, 240 of estimate (SEE) 320 presentation of 221- 2, 487, 488, 490 in regression 306, 314- 15, 319, 336, 347 of sample mean 154, 160, 162, 221- 2 of sample proportion 161- 2, 165, 230 of survival proportion 370, 378 use in constructing confidence intervals 165, 235 Standard Normal deviate see Normal score Standardized difference 457, 458, 459 Standardized mortality ratio 14 Statistic N506 Statistical analysis see Analysis of data Statistical errors in papers 4, 261, 477- 8, 479, 491, 498 in analysis 261, 385- 7, 401- 2, 426- 7, 477, 482, 486- 7 consequences of 453, 482, 491- 2 in design 473- 4, 477- 8, 482- 5 in execution 485 in interpretation 482, 489- 90 of omission 7, 474, 482, 490- 1 in presentation 453- 4, 487- 9, 491 reasons for 492

Statistical guidelines for authors 494, 498 clinical trials 494 epidemiological studies 494 Statistical inference see Inference Statistical modelling 171, 173- 4, 317 see also Model; Regression Statistical significance 168- 71, 174, 455- 6, 472, 489 and clinical importance 170, 177 see also Hypothesis test; P value Statistician 75, 102, 145, 282, 493 Statistics at large 1- 3 in medical research 4- 8, 174, 478- 81 in medicine 3- 4 mistrust of 3 misuse of vii, 481, 486 see also Statistical errors in papers reviews of use of 455, 465- 6, 473, 479- 91 scope of 5- 8 teaching of vii Stem- and- leaf diagram 28 Step function 369, 386 Stepwise regression 340- 5, 349- 50, 355, 389 Streptococcus, group B 224 Streptomycin 440, 478 Stressful life events 269- 70 Stroke 451 Stroke volume (SV) 397- 400 Stuart- Maxwell test 266 Student 181 Student's t test see t test Study design see Design Subgroup analyses 466- 7, 472, 473, 486 Subjects see Sample selection Subscript N505- 6 Subset analyses see Subgroup analyses Suicide 91 Sulphoxidation index (SI) 45, 228, 274- 5 Sum of squares 35, 208, 218- 20, 311 Summary measures/statistics 429- 31, 433, 487, 488 see also Data description Summation (Σ) 35, N508

Sunglasses 216 Superscript N507 Surgery 450 breast cancer 365, 375 cardiac bypass 207 Surveillance bias 99 Survey see Observational study Survival time data 16, 125, 365- 94 actuarial method 371 comparison of groups 371- 6, 379- 85, 386- 7 computing 366, 370, 375, 377, 379, 389, 391 confidence intervals 369- 70, 371, 376, 378- 9, 383- 5, 391 Cox regression 387- 93 design considerations 393 graphical presentation 369, 376, 385, 386- 7, 394 hazard 388, 390- 1 hazard function 388, 392 hazard ratio 375- 6, 383- 4, 385, 390 incorrect analyses 385- 7 Kaplan- Meier survival curve 368- 71, 377- 9, 384, 385, 386, 394 life table 368, 371, 394 logrank test 371- 5, 379- 83, 385, 386, 394 mean survival time 386 median survival time 369, 376, 384- 5, 386 presentation of results 393- 4 prognostic index 390- 1 proportional hazards regression 387- 93 response to treatment 387 sample size 376, 378, 386, 455 survival proportion/probability 366, 367- 71, 376, 377- 9, 384, 386- 7, 388, 390- 1 Sweeteners 102 Swimmers 250- 2, 269 Systematic allocation 446, 485, 494

t distribution 165, 166, 181- 2, 184, 219, 294, 296, 316, 340, N512 compared to Normal distribution 181

t distribution (cont.) table of 521- 2 t test after analysis of variance 211, 219- 20 modified 211 one sample 184- 5, 191, 219, 397, 469 paired 191, 199, 202, 221, 326, 328, 397, 402 presentation of 220- 2 two sample (unpaired) 192, 194, 197, 198, 199, 205, 206, 207, 209, 221, 319, 333, 426, 467, 469  $\mathbf{T_{4}}$  cells 126, 143, 200- 5, 225  $\mathbf{T_{8}}$  cells 200- 5 Tables 42, 488 frequency see Frequency table statistical 514- 45 Tails of distribution 36, 58, 139, 166- 7, 171, 181, 255, 257, 421 Talc 444 Tea 102 Teeth age at eruption 31 decayed, missing and filled 500 number at one year 350 Temperature 41 Test statistic 166, 167, 221, 487 Testosterone 273 Theoretical distributions 50- 71, 171, 175 Therapeutic trial see Clinical trial Thyroxine 198 Ties (tied ranks) 173, 197, 265, 295, 334, 335 Time change over 101- 2 hidden effect of 148- 9 of peak 430 - related data 283, 426- 33 series methods 360 trend 148, 283, 488 Time to run a mile 317 Titre 145 Total lung capacity (TLC) 364 Transcription errors 122- 3, 124, 125 Transformation N510 of data 36, 41- 2, 108, 143, 180, 199, 204, 279, 303, 346, 350, 392, 420

Transformation (cont.) linear 41 logarithmic 36- 7, 41- 2, 60- 2, 126, 136, 143- 5, 199, 200- 3, 205, 287, 303- 6, 392, 400- 1, N510 logit 145- 6, 352 non- linear 41 to Normality 61- 3, 133- 6, 143- 5, 199, 207, 421, N510 of proportion 145- 6, 352 rationale for 143- 5 reciprocal 143- 5 square root 41, 143, 145, 202 Transmitral volumetric flow (MF) 397- 400 Transplantation bone marrow 361, 395 heart- lung 364 kidney 124, 145, 360 liver 368 lung 364 Trapezium rule 433 Treatment allocation 86, 88, 442- 7, 450, 461, 485 Treatment- period interaction 448, 467, 469 Trend see Linear trend; Non- linear trend True positive 357 Trypsin 212- 13, 219- 20 Tumour response 387 size 89, 145, 396 Twins 288- 90, 295 Two- sided (two- tailed) test 167, 170- 1, 177, 214 Type I error 169, 211, 457- 9, N511 Type II error 169, 457- 9, N512 see also Power

Ulcerative colitis 359 Ultrasound 82, 101, 267, 331, 484 Ultraviolet radiation 216 Uncertainty 3, 48, 145, 153, 157, 169, 307, 321, 421 Uncontrolled trial 441, 478 Underwater helicopter escape 334- 6 Unemployment 103

Uniform distribution 71, 120, 146

Unit of investigation 431, 466

Units of measurement 41, 122

Unmarried mothers 102

Unpaired  $t$  test see  $t$  test, two sample

Upper respiratory tract infection 438

Urea nitrogen 161

Uric acid 39

Urinary cotinine excretion 226

Urine flow 323

Valvular heart disease 363

Variability 17, 19, 42, 51, 206, 221

between subjects 189, 401

description of 22- 31, 398, 419, 487, 489

explained 297, 308- 9, 316, 340, 347

quantification of 31- 8

sources of 78

within subjects 189, 206

Variable 17, 108, N505- 6

selection 337, 340- 5, 359, 389

Variance 34, 154, 192

analysis of see Analysis of variance

pooled 192

ratio 197- 8

similar in different study groups 143, 180, 192, 197- 8, 199- 201, 206

180, 192, 197- 8, 199- 201, 206

see also Standard deviation

Vegetarian 94

Ventilation 207

Vision defects 254- 7

Visual analogue scale (VAS) 15- 16, 172

Visual display units (terminals) (VDU) 72, 77, 91, 95, 259- 61

Vitamin supplementation 446- 7, 453

Volunteer bias 100, 446, 484

Vomiting 368, 372- 3, 376, 377- 8

W test 139, 166, 279, 291

W test 139, 291, 303- 6, 330

table for 538- 9

Wash- out period 448, 469, 471

Water

chlorinated 250, 269

Water (cont.)

fluoridated 1, 90, 500

Wedge pressure 149

Weight 12, 59, 84, 279, 298, 336, 343- 4, 345, 347, 423

birth see Birthweight

fetal 279

gain during pregnancy 6

maternal 279

Welch test 198

White cell counts 90

Wilcoxon test

one sample (signed rank sum) 187- 9 table for 531

two paired samples 191, 203- 5, 266, 336

336

effect of transformation of data

203- 5

table for 531

two unpaired (independent) samples see Mann- Whitney test

Withdrawals 132, 366, 447, 463, 471, 473, 490

473,490

Within group (paired) comparison 448

Working history 95

22, N509, N511

Xeromammogram 403- 4

Yates' correction 252- 3, 260

z test 167, 171, 198

z value see Normal score

Zelen's design 449

Zero- one variable see Binary variable

$\alpha$  169, N511

$\beta$  169, N512

$\mu$  54, N511

N509, N511

$\sigma$  35, 54, N511

35, N508, N511

$\chi^{2}$  see Chi squared test

$\pm$  36, 221, 488, N509

! (factorial) 70, 256, N509, N513

$\infty$  N510, N513